
Perimed
Advanced diagnostic instruments for assessing microcirculation and peripheral artery disease.
Date | Investors | Amount | Round |
---|---|---|---|
investor | €0.0 | round | |
* | N/A | Growth Equity non VC | |
Total Funding | 000k |
SEK | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% growth | 2 % | (11 %) | (5 %) | 22 % | (5 %) | 7 % | 9 % |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% profit margin | 1 % | (8 %) | (10 %) | 6 % | 10 % | (1 %) | (3 %) |
EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Perimed AB, founded in 1981 and headquartered near Stockholm, Sweden, specializes in developing, manufacturing, and marketing state-of-the-art diagnostic equipment for the assessment of microcirculation, peripheral perfusion, and peripheral artery disease. The company serves a diverse clientele, including clinical practitioners and researchers, with a strong presence in the medical device market. Perimed's business model revolves around the sale of advanced diagnostic instruments and related services, generating revenue through direct sales, partnerships, and government contracts. Notably, Perimed has secured agreements with entities such as Lovell Government Services, expanding its sales channels to include Federal, State, and Local Governments in the United States. The company's vision is to save limbs, lives, and reduce human suffering by providing accurate diagnostic tools for patients with ischemia.
Keywords: microcirculation, peripheral perfusion, peripheral artery disease, diagnostic equipment, medical devices, clinical use, research, ischemia, government contracts, Sweden.